What Moolec Science’s 15-for-1 share consolidation means for holders

Moolec Science (MLEC) shareholders approved voluntary liquidation. Nasdaq will delist its shares, effective November 3, 2026, due to the winding-up and public interest considerations.

UBS kept its Buy rating on Bank of America but reduced its price target to $62 from $67, citing a 7.5% decrease. The new target suggests a 25.1% upside from the stock's Nov 2 close of $49.57. Recent analyst notes have set price targets between $58 and $61.

Fortuna Mining Corp. (FSM, FVI) announced progress on its Diamba Sud gold project in Senegal, receiving a Notice of Admissibility for its Exploitation Permit. The company expects final approval by Q4 2026 and aims for first gold in mid-2028. Fortuna targets 60% growth in annual gold production to 500,000 ounces by mid-2028, supported by the Diamba Sud project and a 30% plant expansion at its Séguéla mine.

Novartis' experimental heart drug, pelacarsen, failed to reduce heart attack and stroke risk in a large trial, despite lowering Lp(a) levels by 80%. Doctors and investors await detailed results. Other drugmakers, like Amgen and Eli Lilly, are developing similar drugs. Novartis' stock dropped 16% following the news. The trial's outcome may impact future Lp(a)-targeting drug development.

Leonardo DRS (DRS) will provide power and cooling systems for AeroVironment's (AVAV) 30-kilowatt LOCUST X3 laser weapon, part of the U.S. Army's Enduring-High Energy Laser (E-HEL) program. The E-HEL is the Army's first production contract for a high-energy laser weapon system, aimed at countering unmanned aircraft threats. DRS's role supports AV's production of the LOCUST X3 for the Army's counter-UAS operations.

Wedbush initiated coverage on Oklo Inc. (NYSE: OKLO) with an outperform rating and a $36 price target, citing its progress in nuclear technology. The stock trades near its 52-week low, with analyst targets ranging from $14 to $122. Oklo's operational track record and diversified business model were highlighted as key strengths. The company is set to release earnings on November 6, with options data suggesting a potential 9.5% stock movement.